# Quanta Therapeutics Reports 55% Response Rate for QTX3034 in KRAS G12D Endometrial Cancer

> Quanta Therapeutics reported a 55% objective response rate for QTX3034 monotherapy in 11 patients with KRAS G12D-mutant endometrial cancer at the ENA Symposium 2026.

- Published: 2026-11-20T12:36:05+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-20/quanta-qtx3034-endometrial-cancer-response
- Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/20/3407355/0/en/quanta-presents-class-leading-monotherapy-data-for-qtx3034-in-kras-g12d-mutant-advanced-endometrial-cancer-at-the-eortc-nci-aacr-symposium.html)

## Key takeaways

- QTX3034 monotherapy achieved a 55% objective response rate in 11 patients with KRAS G12D-mutant endometrial cancer, including one complete response.
- The median duration of response was 9.7 months and the median time to response was 1.3 months.
- Four of five patients with endometrioid histology, or 80%, achieved an objective response.

Quanta Therapeutics reported a 55% objective response rate for its oral KRAS inhibitor QTX3034 as a monotherapy in 11 patients with KRAS G12D-mutant endometrial cancer, including one complete response. The data were presented at the EORTC-NCI-AACR Symposium 2026, [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/20/3407355/0/en/quanta-presents-class-leading-monotherapy-data-for-qtx3034-in-kras-g12d-mutant-advanced-endometrial-cancer-at-the-eortc-nci-aacr-symposium.html) reported on November 20, 2026.

## Quanta's QTX3034 Monotherapy Results

[Quanta Therapeutics](https://akta.pro/company-profiles/0000mqg/quanta-therapeutics) is a privately held, clinical-stage biopharmaceutical company developing oral small-molecule inhibitors of KRAS G12D and G12V for RAS-driven cancers, including pancreatic, colorectal, lung and endometrial tumors. The 11 patients in the endometrial cancer cohort had received a median of four prior lines of therapy, and all had mismatch repair-proficient tumors and prior chemotherapy and immune checkpoint inhibitor therapy.

Responses occurred rapidly, with a median time to response of 1.3 months, and were durable, with a median duration of response of 9.7 months. Four of five patients with endometrioid histology, or 80%, achieved an objective response. QTX3034 was generally well tolerated, with primarily low-grade adverse events and no treatment-related adverse events leading to discontinuation.

"These results provide encouraging evidence that direct KRAS inhibition can drive meaningful and durable tumor responses in patients with KRAS G12D-mutant endometrial cancer who have progressed following established therapies," said Judy S. Wang, M.D., of Florida Cancer Specialists/Sarah Cannon Research Institute and presenting author of the study.

## Quanta's Funding and Pipeline

According to akta.pro [company records](https://akta.pro/company-data), Quanta has raised over $142 million since its founding in 2018, including a $50.7 million Series D in May 2023. The company has three KRAS inhibitor programs in clinical development: QTX3034, QTX3046 and QTX3544. KRAS mutations occur in approximately 25% of all human cancers.

## Earlier QTX3034 Data at ESMO

In October 2026, Quanta presented positive clinical data for QTX3034 combined with cetuximab and/or chemotherapy in KRAS G12D-mutant colorectal cancer at ESMO 2026, showing a 25% overall response rate and 75% disease control with no new safety signals, GlobeNewswire reported. Earlier that month, the FDA granted Fast Track designation for the drug in KRAS G12D-mutant patients, according to Business & Financial.

## What to Watch Next

Quanta said the endometrial cancer data support further development of QTX3034 in this molecularly defined subset. The company has not announced a date for that next study.

## Companies in this story

- [Quanta Therapeutics company profile](https://akta.pro/company-profiles/0000mqg/quanta-therapeutics) · website: https://www.quantatx.com

---
News for Agent · https://newsforagent.com/llms.txt
